OTCMKTS:BNXTF BioNxt Solutions (BNXTF) Stock Price, News & Analysis $0.29 -0.03 (-9.71%) As of 11:35 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesShort InterestBuy This Stock About BioNxt Solutions Stock (OTCMKTS:BNXTF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioNxt Solutions alerts:Sign Up Key Stats Today's Range$0.29▼$0.2950-Day Range$0.29▼$0.4452-Week Range$0.26▼$0.80Volume3,000 shsAverage Volume2,710 shsMarket Capitalization$35.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BioNxt Solutions Inc. (OTCMKTS:BNXTF) is a life sciences company specializing in advanced proteomics, metabolomics and bioinformatics solutions. The company’s platform combines state-of-the-art mass spectrometry and chromatography workflows with cloud-based data analysis tools, enabling high-throughput characterization of proteins, metabolites and other biomolecules for research and development purposes. BioNxt Solutions offers contract research services to clients in the pharmaceutical, biotechnology and academic sectors, providing end-to-end support from sample preparation through to data interpretation. Its services include quantitative proteomic profiling, metabolomic screening, post-translational modification mapping and custom assay development. By integrating proprietary protocols with machine learning algorithms, the company aims to accelerate target discovery, biomarker identification and drug development projects. Headquartered in Vancouver, British Columbia, BioNxt Solutions serves customers across North America, Europe and Asia, supporting projects in areas such as oncology, neurology and infectious disease research. The company’s multidisciplinary leadership team brings together expertise in analytical chemistry, computational biology and commercial operations to drive growth and innovation in the rapidly evolving omics market. Committed to expanding its global footprint, BioNxt Solutions continues to invest in research and development, strategic partnerships and infrastructure enhancements. The company’s long-term strategy focuses on advancing precision medicine by delivering scalable, high-resolution analytical platforms and data-driven insights that meet the complex needs of modern life science and healthcare industries.AI Generated. May Contain Errors. Read More Receive BNXTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNxt Solutions and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BNXTF Stock News HeadlinesBioNxt Solutions Inc. (OTCMKTS:BNXTF) Sees Large Growth in Short InterestMay 12, 2026 | americanbankingnews.comBioNxt Solutions Inc.: BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 CountriesApril 7, 2026 | finanznachrichten.deBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.May 19 at 1:00 AM | Weiss Ratings (Ad)BioNxt Solutions Inc.: BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery PlatformMarch 24, 2026 | finanznachrichten.deBioNxt Solutions Inc.: BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and EuropeMarch 17, 2026 | finanznachrichten.deBioNxt Solutions Inc.: BioNxt Announces Closing of Shares for Debt SettlementFebruary 26, 2026 | finanznachrichten.deBioNxt Solutions Inc.: BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple SclerosisFebruary 17, 2026 | finanznachrichten.deBioNxt Solutions Inc.: BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug DeliveryFebruary 5, 2026 | finanznachrichten.deSee More Headlines BNXTF Stock Analysis - Frequently Asked Questions How have BNXTF shares performed this year? BioNxt Solutions' stock was trading at $0.4430 at the start of the year. Since then, BNXTF stock has decreased by 34.7% and is now trading at $0.2892. How were BioNxt Solutions' earnings last quarter? BioNxt Solutions Inc. (OTCMKTS:BNXTF) issued its quarterly earnings data on Wednesday, April, 29th. The company reported ($0.01) earnings per share for the quarter. How do I buy shares of BioNxt Solutions? Shares of BNXTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings4/29/2026Today5/19/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryN/A Current SymbolOTCMKTS:BNXTF CIKN/A Webwww.xphyto.com Phone780-818-6422FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.43 million Net MarginsN/A Pretax Margin-40,618.18% Return on EquityN/A Return on Assets-724.88% Debt Debt-to-Equity RatioN/A Current Ratio0.22 Quick Ratio0.22 Sales & Book Value Annual Sales$20 thousand Price / Sales1,771.21 Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-5.78Miscellaneous Outstanding Shares122,490,000Free FloatN/AMarket Cap$35.42 million OptionableNot Optionable Beta0.69 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:BNXTF) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNxt Solutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNxt Solutions With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
